

BENCHMARKING COVID-19 - AN ACTUARIAL PERSPECTIVE

March 31, 2020

CONFIDENTIALITY

Our clients' industries are extremely competitive, and the maintenance of confidentiality with respect to our clients' plans and data is critical. Oliver Wyman rigorously applies internal confidentiality practices to protect the confidentiality of all client information.

Similarly, our industry is very competitive. We view our approaches and insights as proprietary and therefore look to our clients to protect our interests in our proposals, presentations, methodologies and analytical techniques. Under no circumstances should this material be shared with any third party without the prior written consent of Oliver Wyman.

© Oliver Wyman

BACKGROUND

COVID-19 is an illness caused by the novel coronavirus; this is from the same family of viruses that cause the common cold as well as SARS and MERS

Transmission rate

- ~2X the Flu
- Measured as number of cases an infected person causes → R-naught (R0)
 - The Flu R0 = 1.3
 - COVID-19 R0 between 2 and 3
- Even in asymptomatic and mild cases, individuals will be contagious

Containment

- Typically anything with an R0 greater than 1 warrants countermeasures like quarantines
- The incubation period is far longer at 2-14+ days vs. the Flu at 1-4 days, thus creating additional containment issues
- Data suggests that viral shedding continues beyond symptom resolution

Mortality

- 20% of cases have been considered severe, requiring hospitalization for supportive care
- Global case fatality rate (as of March 29): 4.7% of confirmed cases, much higher than the Flu
- Mortality is much higher for the elderly and those with pre-existing conditions

Unknowns


- COVID-19 is still relatively new with many unknown factors; insurers' exposure to this risk will need to be monitored closely
- Mortality mitigants:
 - Mortality rate could decrease over time as milder cases (~80% of all cases) are often going undiagnosed
 - We expect mortality rate to decrease as testing expands and more cases are identified
- Mortality accelerants:
 - Hospital systems risk being overtaxed (ICU beds, ventilators, PPE) meaning case fatality rates could rise further

Source: Bing COVID-19 Tracker, China CDC, CDC, MedRxiv

COVID-19 SPREAD GLOBALLY

As of March 31st, 2020

- >800K cases reported in 179 countries and territories
- ~39K reported deaths




- First reported in Wuhan, China, on **December 31, 2019**
- Declared a global pandemic by the World Health Organization on **March 11, 2020**

1. Countries included: All Countries in "European Region" Sub-region in WHO Situation Report
Source: Map from CDC ([link](#)), numbers from John Hopkins University & Medicine ([link](#)) as of March 31, 2020

COVID-19 SPREAD IN THE US

New York is at the epicenter, contributing over **42%** of confirmed US cases




COVID-19 TRENDS AND SPREAD OF THE DISEASE

The number of new cases in China has slowed – likely due to significant containment measures – as the outbreak spreads to other countries


Confirmed Cases of COVID-19

Cumulative Number of Cases as of March 29



New Cases Per Day of COVID-19


New Cases Per Day as of March 29



Source: John Hopkins University & Medicine Coronavirus Resource Centre

1. Until February 17, the WHO situation reports included only laboratory confirmed cases causing a spike in total cases. Some sources include this update as of February 13. The jump due to inclusion of non lab confirmed cases is not included in the new cases data in WHO situation reports.; 2. Includes countries categorized under "European region" based off of latest WHO Situation Reports

MOST COUNTRIES – INCLUDING THE US – CONTINUE TO SEE EXPONENTIAL GROWTH; CHINA AND SOUTH KOREA HAVE FLATTENED THE CURVE



- Lack of broad testing early, followed by rapid ramp-up may explain part of steep growth rate
- Response left largely to individual states
- More than half of states implemented state-wide stay at home orders between March 19 and April 1



- Initial ring-fencing limited to Lombardy, at 8,000 cases (day 15 in chart), with ongoing travel still permitted
- Broader shutdown at 12,000 cases (day 17 in chart)



- Enforced city-wide quarantine of Wuhan post-outbreak
- Early containment outside Hubei halted growth
- Mobile monitoring / enforcement (via WeChat, etc.)




- Massive early testing (as of March 28, >6,500 tests per million vs. US estimated ~2,000 tests per million people)
- Quarantined patients monitored via mobile app
- Epidemic response in place from SARS outbreak

Sources: JCSSE, local news and county health departments, as of March 17. Pre-WHO China data from [NHC](#) Containment sources: [China](#), [S. Korea](#), [US](#) and [testing](#) stats, [Italy](#)
 100th case on: Italy: February 23, S. Korea: February 20, US: March 3, China: before January 18, UK: March 5, France: February 29, Germany: March 1; Spain March 2. Data from JHU
 March 29, 2020
 © Oliver Wyman

THE CASE COUNT OF COVID-19 CONTINUES TO GROW ACROSS THE UNITED STATES

Confirmed Cases Since Day 0 by US Metro area

Log scale




Data: USA Facts County Level Data as of March 29, 2020. Stay at home orders data from New York Times.

COVID-19 TRENDS AND SPREAD OF THE DISEASE

Daily death rates indicate that suppression, aggressive testing, and active tracing / isolation strategies (as seen in countries like South Korea) can effectively ease the burden on the healthcare system, leading to lower death rates

Number of daily COVID-19 deaths by country




Source: John Hopkins University & Medicine Coronavirus Resource Centre
100th case on: Italy: February 23, S. Korea: February 20, US: March 3, China: before January 18, UK: March 5, France: February 29, Germany: March 1; Spain March 2. Data from JHU.
© Oliver Wyman

HOW DOES COVID-19 COMPARE TO OTHER DISEASE OUTBREAKS?

COVID-19 is currently more deadly than the Flu, but the science on transmission and mortality continues to evolve

Fatality rate¹
Log scale



Additional details

- R-naught (R0) represents the number of cases an infected person will cause. R0 for COVID-19 is currently estimated at between 2 and 3 (with edge of range estimates closer to 1.4 and 3.6), which means each person infects 2-3 others³; R0 for the seasonal flu is around 1.3⁴
- The global case fatality rate for confirmed COVID-19 cases is currently 4.7%⁵ according to WHO's reported statistics versus 0.1% for the seasonal flu; the rate varies significantly by country (e.g., Italy – 11.03%, South Korea – 1.59%⁵)
- We expect case fatality rates to fluctuate as testing expands identifying more cases and as existing cases are resolved

▲ Denotes Coronaviruses

1. New York Times ([link](#)) for fatality and R-naught comparisons, CDC timelines for case numbers (selected link: CDC [SARS](#) timeline); 2. Updated CDC estimates ([link](#)); 3. The R0 for the coronavirus was estimated by the WHO to be between 1.4 -2.5 (end of January estimate) ([link](#)), other organizations have estimated an R0 ranging between 2-3 or higher ([link](#)); 4. CDC Paper ([link](#)); 5. Calculated as Number of Deaths / Total Confirmed Cases as reported by John Hopkins University.

COMPARISON TO PAST EVENTS

The current COVID-19 death toll is a fraction of historical events; however, we are in the early stages and this number has potential to expand greatly

Year	Description	Region	Global death toll (000s, approx.)	US death toll (000s, approx.)	Brackets: additional # of deaths per 1000 persons
1906	Great Earthquake and Fire	San Francisco, CA	3	3	
1918	Spanish Flu	International epidemic	50,000	675 [6.54]	
1928	Okeechobee Hurricane	Puerto Rico, Bahamas, U.S.	4	2.5 [0.02]	
1931	Central China Floods	Central China	3,700	0	
1952	Polio Epidemic	U.S.	3.1	3.1 [0.02]	
1957	Asian Flu	International epidemic	2,000	70 [0.41]	
1968	Hong Kong Flu	International epidemic	1,000	36 [0.18]	
1980	Summer heat wave	California	10	10 [0.04]	
2004	Indian Ocean Earthquake	Bangladesh and West India	230	0	
2005	Hurricane Katrina	Southern U.S.	1.8	1.8 [0.01]	
2009	H1N1 Flu	International epidemic	280	12.5 [0.04]	
2020	COVID-19	International epidemic	33.9	3.7 [0.01]	3,721 US deaths reported to date (March 31), but evolving


Values in blue mark pandemic events

Source: Oliver Wyman research and analysis, John Hopkins University & Medicine, as of March 31, 2020

CASE FATALITY RATE (CFR) BY COUNTRY

While the global CFR is a useful metric to understand COVID-19, country-specific CFRs range by an order of magnitude

CFR by country¹



What is driving the variation?


- **Position along the trajectory of the outbreak:** For many countries (e.g., Europe, US), the vast majority of cases have not yet resolved and the CFR is changing rapidly
- **Breadth of testing:** Broader testing leads to a larger confirmed base of patients, decreasing CFR
- **Distribution of key risk factors within the population:** Age, gender and pre-existing conditions have a significant influence on mortality; countries with higher CFRs have a population skewed towards these risk factors (e.g., Italy has the second oldest population on earth)
- **Health system threshold:** Every country has a health system capacity, that when exceeded, will result in the inability to provide sufficient support to all patients thereby resulting in a higher CFR

Note that case fatality rates are still unstable as greater than 80% of cases outside of China are still active

1. Calculated as Number of Deaths / Total Confirmed Cases as reported by Johns Hopkins University as of March 29, 2020
© Oliver Wyman

DEATHS BY AGE

COVID-19 exhibits a different mortality curve than historical pandemics; the chart below shows deaths per 100,000 persons in each age group for the 1918 Flu pandemic, 1911-1917 interpandemic period, and COVID-19



Commentary

- Most pandemics follow a “U-shaped” mortality curve where most deaths are due to secondary pneumonia infection in immunocompromised people (mostly young and old)
- The 1918 Spanish Flu was partly so devastating because the mortality rates spiked for young adults likely due to “cytokine storm”, resulting in its “W-shape”
- COVID-19 follows an unusual “L-shaped” distribution that disproportionately impacts individuals over 55 years old
- Exposure to COVID-19 needs to be considered in the context of each insurer’s inforce block demographics and may not match the overall impact to the general population

Potential COVID-19 mortality impacts should be modeled by age rather than a single additive factor


CASE FATALITY RATE (CFR) BY AGE AND GENDER

Significantly higher death rates occur among the elderly and males


Case Fatality Rate by Specific Patient Characteristics

Based on all confirmed cases in China as of February 11, 2020 and Italy as of March 17, 2020

by Age



by Gender



Source: China CDC Weekly. Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020, Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy - Graziano Onder, MD, PhD; Giovanni Rezza, MD; Silvio Brusaferro, MD, Italy's National Health Institute (ISS)


CASE FATALITY RATE (CFR) BY COMORBIDITY

Significantly higher death rates occur among those with underlying conditions

Case Fatality Rate by Specific Patient Characteristics

All confirmed cases in China as of February 11, 2020

by Comorbid Condition



Source: China CDC Weekly, Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020, American Heart Association

Notes: Data includes 44,672 confirmed cases reported through February 11, 2020, which is the latest data available as of March 29, 2020.

KEY ASSUMPTIONS TO DETERMINE RANGE OF PANDEMIC SCENARIOS

Estimating a range of infection and mortality rates is essential to determining the potential impact of COVID-19 given rapidly emerging data and a quickly changing situation

	Infection rate (% of population with disease)	Mortality rate (% of deaths in infected population)
COVID-19	<ul style="list-style-type: none"> • Wuhan, China (ground 0) infection rate: ~1% • Quarantine and social distancing measures are being implemented globally • Vaccines are being developed, but not expected to be available on a large scale for a year or more 	<ul style="list-style-type: none"> • Mortality rate expected to be closer to 1% when proper healthcare can be provided • Rate increases significantly when healthcare system is overloaded, as seen in Italy (11.0% rate) • Virus-fighting drugs are in the process of being developed
Other pandemics	<ul style="list-style-type: none"> • Annual Flu infection rates range from ~3% to 16% • 1918 Spanish Flu infection rate was ~28% of the US population 	<ul style="list-style-type: none"> • Annual Flu mortality rate range from 0.1% to 0.3% • 1918 Spanish Flu mortality rate was ~2.5% for the US population (higher globally)
Potential assumption ranges (US)	<ul style="list-style-type: none"> • Rate of 0.5 – 30% 	<ul style="list-style-type: none"> • Base case: 0.5 – 1% • Stress: 2%+ if healthcare system overloaded
What to monitor	<ul style="list-style-type: none"> • Effectiveness of containment measures • When containment measures are lifted, and if subsequent outbreak waves occur • Pharmaceutical treatments 	<ul style="list-style-type: none"> • Stability of healthcare system in “hot spots” • Amount of testing (also impacts reported infection rate)


Source: United States Department of Health and Human Services, Johns Hopkins University , as of March 29, 2020

COVID-19 IS UNLIKELY TO REPEAT 1918 SPANISH FLU SCENARIO; HOWEVER, HIGHLY DEPENDENT ON HEALTHCARE SYSTEM STABILITY

Additional deaths per 1,000 people


Range of 1 year shocks in US; moderate pandemic scenario = 0.7 / 1,000 additional deaths in one year

Excess deaths / 1,000



COVID-19 ILLUSTRATIVE MORTALITY SCENARIOS

Insurers can begin to understand the range of potential outcomes by applying additional deaths in their models; a given scenario may be framed using different combinations of underlying assumptions




OUR SCENARIO FORECAST GENERATOR HELPS TO QUANTIFY **NEAR TERM** SCENARIOS

The model paints the picture of the “book-end” scenarios – and a range of trajectories in between – up to 8 weeks out and is now incorporated into our hospital supply and demand model

OW COVID-19 Scenario Generator

Modeling Assumptions	
Current Number of Confirmed Cases	476 <small>Current number of Confirmed Cases for forecast region</small>
Delay Until Containment Effort Starts (days)	7 <small>Estimated days until increased containment measures are implemented</small>
Expected Effectiveness of Containment Effort	Medium <small>Expected levels of containment measures (testing, social distancing, quarantines)</small>
Current Daily Growth Rate in Cases	50% <small>is ideally calculated as: (Confirmed Cases(day)/Confirmed Cases(prior day)) - 1. If data are not available, see</small>

Scenario Output									
Case Type	Today	Week 1	Week 2	Week 3	Week 4	Week 5	Week 6	Week 7	Week 8
Cumulative Confirmed Cases	476	5,698	39,479	128,744	243,284	340,545	406,033	444,917	466,518
New Confirmed Cases		5,222	33,782	89,264	114,540	97,261	65,488	38,884	21,601



Oliver Wyman created a model to forecast the number of confirmed cases in a region or area based on the starting number of cases, daily case growth rates, the speed with which officials move to enact containment measures, and the effectiveness of those measures.

The model has been applied to forecast scenarios for hospital capacity in US geographies.


Link to the model can be found at <https://oliverwymangroup.wufoo.com/forms/s12hwj5h0ggcqx1/>

OW COVID-19 US Hospital Supply / Demand Model

Key Parameters	
MSA Selection	IL - Chicago <small>For custom market definition, select "Custom Market" and adjust Counties to include / exclude in Column G in "County Summary" tab</small>
MSA Population	8,679,808
Current Number of Confirmed Cases	1,500 <small>Current number of Confirmed Cases for forecast region</small>
Current Daily Growth Rate in Cases	30% <small>This is ideally calculated as: (Confirmed Cases(day)/Confirmed Cases(prior day)) - 1. If data are not available, see guiding logic on the right</small>
Delay Until Containment Effort Starts (days)	7 <small>Estimated days until increased containment measures are implemented</small>
Expected Effectiveness of Containment Effort	Low <small>See text box to the right for further explanation. Recent trends for most markets in the US, as well as most democratic countries abroad, follows the Low containment growth path</small>
Include Children Hospital Bed Capacity?	No

Baseline MSA Capacity & Utilization				
	User Input		Default Values	
	Med-Surg Beds	ICU Beds	Med-Surg Beds	ICU Beds
Average Free Beds	7,141	970	7,141	970
Average Occupied Beds	9,759	1,500	9,759	1,500
Total Beds	16,900	2,470	16,900	2,470
Average Utilization Rate	58%	61%	58%	61%

Note: You must input both Avg. Occupied Beds and Total Beds to override Default Values



READ OUR LATEST INSIGHTS ABOUT COVID-19 AND ITS GLOBAL IMPACT ONLINE

Oliver Wyman and our parent company Marsh & McLennan (MMC) have been monitoring the latest events and are putting forth our perspectives to support our clients and the industries they serve around the world. Our dedicated COVID-19 digital destination will be updated daily as the situation evolves.



[Visit our dedicated COVID-19 website](#)



QUALIFICATIONS, ASSUMPTIONS AND LIMITING CONDITIONS

This report is for the exclusive use of the Oliver Wyman client named herein. This report is not intended for general circulation or publication, nor is it to be reproduced, quoted or distributed for any purpose without the prior written permission of Oliver Wyman. There are no third party beneficiaries with respect to this report, and Oliver Wyman does not accept any liability to any third party.

Information furnished by others, upon which all or portions of this report are based, is believed to be reliable but has not been independently verified, unless otherwise expressly indicated. Public information and industry and statistical data are from sources we deem to be reliable; however, we make no representation as to the accuracy or completeness of such information. The findings contained in this report may contain predictions based on current data and historical trends. Any such predictions are subject to inherent risks and uncertainties. Oliver Wyman accepts no responsibility for actual results or future events.

The opinions expressed in this report are valid only for the purpose stated herein and as of the date of this report. No obligation is assumed to revise this report to reflect changes, events or conditions, which occur subsequent to the date hereof.

All decisions in connection with the implementation or use of advice or recommendations contained in this report are the sole responsibility of the client. This report does not represent investment advice nor does it provide an opinion regarding the fairness of any transaction to any and all parties.